FDA Grants Priority Review To Genentech's Glofitamab To Treat R/R Large B-cell Lymphoma
6/1 07:16
(RTTNews) - Genentech, a member of Swiss drug major Roche Group (RHHBY), announced Friday that the U.S. Food and Drug Administration has accepted its Biologics License Application or BLA and granted Priority Review for glofitamab to treat people with relapsed or refractory large...